182 related articles for article (PubMed ID: 34540486)
1. False-Negative 18F-Fluorodeoxyglucose PET/CT in Malignant Pleural Mesothelioma.
Corbin H; Packer CD
Cureus; 2021 Aug; 13(8):e17263. PubMed ID: 34540486
[TBL] [Abstract][Full Text] [Related]
2. Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma.
Abe Y; Tamura K; Sakata I; Ishida J; Ozeki Y; Tamura A; Uematsu K; Sakai H; Goya T; Kanazawa M; Machida K
Oncol Rep; 2012 Feb; 27(2):333-8. PubMed ID: 22024889
[TBL] [Abstract][Full Text] [Related]
3. Pleural involvement of diffuse large B-cell lymphoma mimicking malignant pleural mesothelioma.
Ito T; Fujita K; Okamura M; Okuno Y; Saito Z; Kanai O; Nakatani K; Moriyoshi K; Mio T
Respir Med Case Rep; 2020; 31():101206. PubMed ID: 32944500
[TBL] [Abstract][Full Text] [Related]
4. The Role of 18F-FDG PET/CT Integrated Imaging in Distinguishing Malignant from Benign Pleural Effusion.
Sun Y; Yu H; Ma J; Lu P
PLoS One; 2016; 11(8):e0161764. PubMed ID: 27560933
[TBL] [Abstract][Full Text] [Related]
5. 18F-fluorodeoxyglucose positron emission tomography in malignant pleural mesothelioma: diagnostic and prognostic performance and its correlation to pathological results.
Lococo F; Rena O; Torricelli F; Filice A; Rapicetta C; Boldorini R; Paci M; Versari A
Interact Cardiovasc Thorac Surg; 2020 Apr; 30(4):593-596. PubMed ID: 32003806
[TBL] [Abstract][Full Text] [Related]
6. Malignant pleural mesothelioma presenting as low back pain: diagnosed by bone scan coordinating with F-18 FDG PET/CT.
Huang YC; Tu DG; Wu JD; Lee MY
Spine (Phila Pa 1976); 2009 Oct; 34(21):E780-3. PubMed ID: 19934799
[TBL] [Abstract][Full Text] [Related]
7. Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study.
Yildirim H; Metintas M; Entok E; Ak G; Ak I; Dundar E; Erginel S
J Thorac Oncol; 2009 Dec; 4(12):1480-4. PubMed ID: 19875971
[TBL] [Abstract][Full Text] [Related]
8. An Autopsied Case of Malignant Sarcomatoid Pleural Mesothelioma in Which Chest Pain Developed Several Months Earlier without Abnormality on Imaging.
Yaguchi D; Ichikawa M; Inoue N; Kobayashi D; Matsuura A; Shizu M; Imai N; Watanabe K
Case Rep Oncol; 2015; 8(3):439-46. PubMed ID: 26600776
[TBL] [Abstract][Full Text] [Related]
9. Extensive Skeletal Muscle Metastases in Malignant Pleural Mesothelioma Detected by FDG PET/CT.
Yilmaz M; Kandemir O; Tutar E
World J Nucl Med; 2023 Dec; 22(4):293-296. PubMed ID: 38152103
[TBL] [Abstract][Full Text] [Related]
10. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography.
Bénard F; Sterman D; Smith RJ; Kaiser LR; Albelda SM; Alavi A
Chest; 1998 Sep; 114(3):713-22. PubMed ID: 9743156
[TBL] [Abstract][Full Text] [Related]
11. Is 18F-FDG PET/CT capable of differential diagnosis from tuberculous pleurisy from malignant mesothelioma?
Özmen Ö; Tatci E; Demiröz ŞM; Tazeler Z; Demirağ F
Nucl Med Commun; 2021 Jun; 42(6):672-677. PubMed ID: 33625184
[TBL] [Abstract][Full Text] [Related]
12. Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?
Sharif S; Zahid I; Routledge T; Scarci M
Interact Cardiovasc Thorac Surg; 2011 May; 12(5):806-11. PubMed ID: 21266493
[TBL] [Abstract][Full Text] [Related]
13. Asymptomatic primary tuberculous pleurisy with intense 18-fluorodeoxyglucose uptake mimicking malignant mesothelioma.
Shinohara T; Shiota N; Kume M; Hamada N; Naruse K; Ogushi F
BMC Infect Dis; 2013 Jan; 13():12. PubMed ID: 23317113
[TBL] [Abstract][Full Text] [Related]
14. What is the best way to diagnose and stage malignant pleural mesothelioma?
Zahid I; Sharif S; Routledge T; Scarci M
Interact Cardiovasc Thorac Surg; 2011 Feb; 12(2):254-9. PubMed ID: 21044972
[TBL] [Abstract][Full Text] [Related]
15. A case of malignant mesothelioma detected hydropneumothorax.
Ema T; Funai K; Kawase A; Oiwa H; Iizuka S; Shiiya N
J Thorac Dis; 2018 Apr; 10(4):E281-E284. PubMed ID: 29850169
[TBL] [Abstract][Full Text] [Related]
16. Pleural fluid cytological yield and visceral pleural invasion in patients with epithelioid malignant pleural mesothelioma.
Pinelli V; Laroumagne S; Sakr L; Marchetti GP; Tassi GF; Astoul P
J Thorac Oncol; 2012 Mar; 7(3):595-8. PubMed ID: 22307010
[TBL] [Abstract][Full Text] [Related]
17. Early-stage Clinical Characterization of Malignant Pleural Mesothelioma.
Negi Y; Kuribayashi K; Funaguchi N; Doi H; Mikami K; Minami T; Takuwa T; Yokoi T; Hasegawa S; Kijima T
In Vivo; 2018; 32(5):1169-1174. PubMed ID: 30150440
[TBL] [Abstract][Full Text] [Related]
18. Dual time point FDG PET for evaluation of malignant pleural mesothelioma.
Yamamoto Y; Kameyama R; Togami T; Kimura N; Ishikawa S; Yamamoto Y; Nishiyama Y
Nucl Med Commun; 2009 Jan; 30(1):25-9. PubMed ID: 19306511
[TBL] [Abstract][Full Text] [Related]
19. The role of FDG PET-CT in differential diagnosis of pleural pathologies.
Elboga U; Yılmaz M; Uyar M; Zeki Çelen Y; Bakır K; Dikensoy O
Rev Esp Med Nucl Imagen Mol; 2012; 31(4):187-91. PubMed ID: 23067687
[TBL] [Abstract][Full Text] [Related]
20. Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.
Schaefer NG; Veit-Haibach P; Soyka JD; Steinert HC; Stahel RA
Eur J Radiol; 2012 Jan; 81(1):e19-25. PubMed ID: 21129871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
